ArticleFrontiers in physiology2022
Treatment of wild-type mice with 2,3-butanediol, a urinary biomarker of
Article in Frontiers in physiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 16 citations in OpenAlex.
- The 2R, 3R isomer of 2, 3-butanediol prevents weight gain and decreases plasma glucose concentration of mice fed a fat-enriched diet.Frontiers in physiology · 2026Article
- Phenotypic and metabonomics studies of FMOs in C. elegans and their roles in lifespan extension.Metabolomics : Official journal of the Metabolomic Society · 2025Article
- Clinical and metabolic phenotypes of Oxford Biobank subjects with variations in human flavin-containing monooxygenase 5 (FMO5).Metabolomics : Official journal of the Metabolomic Society · 2025Article
- Transcriptional analysis of C. elegans fmos at different life stages and their roles in ageing.Molecular genetics and genomics : MGG · 2024Article
- Analysis of the Urine Volatilome of COVID-19 Patients and the Possible Metabolic Alterations Produced by the Disease.Metabolites · 2024Article
- Flavin-containing monooxygenase (FMO): Beyond xenobiotics.BioEssays : news and reviews in molecular, cellular and developmental biology · 2024Review
- Puerarin ameliorates non-alcoholic fatty liver disease by inhibiting lipid metabolism through FMO5.Frontiers in pharmacology · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
Abstract
We previously showed that
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.